A 24-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Evaluation of the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease (MMSE 10-20).

Trial Profile

A 24-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Evaluation of the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease (MMSE 10-20).

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2016

At a glance

  • Drugs Rivastigmine (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 24 Aug 2015 Ono Pharmaceutical obtained the approval for partial changes in the manufacturing and marketing authorization of transdermal patch therapy RIVASTACH PATCH to treat mild-to-moderate Alzheimer-type dementia to add "dosage and administration", in which the dose is increased to the maintenance dose by one step.
    • 20 Jul 2011 Results presented at the 2011 International Conference on Alzheimer's Disease.
    • 20 May 2009 Actual number of patients (859) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top